# US 2013/0096139 A1 · Compounds Useful as Inhibitors of ATR Kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0096139 A1
- Document ID: US20130096139A1
- Status: Published application
- Kind: A1
- Application number: 13/631,727
- Filed: 2012-09-28
- Published: 2013-04-18
- Earliest claimed: 2011-09-30
- Assignees: Vertex Pharmaceuticals Incorporated
- Inventors: Jean-Damien Charrier; Pierre-Henri Storck; John Studley; Francoise Yvonne Theodora Marie Pierard
- Web page: https://patentgrep.com/patent/US20130096139A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/497: containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 413/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A method for treating cancer in a patient comprising administering a compound of claim 1 or a pharmaceutically acceptable derivative thereof.

### Claim 4 (depends on 3)

The method of claim 3, further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 4)

The method of claim 4, wherein said DNA-damaging agent is selected from ionizing radiation, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent, or an alkyl sulphonates.

### Claim at position 7

8-16. (canceled)

### Claim 17 (depends on 4)

The method of claim 4, wherein the DNA-damaging agent is selected from one or more of the following: Cisplatin, Carboplatin, gemcitabine, Etoposide, Temozolomide, or ionizing radiation.

### Claim 18

(canceled)

### Claim 19 (depends on 3)

The method of claim 3, wherein said cancer is selected from a cancer of the lung or the pancreas.

### Claim 20

(canceled)

### Claim 21 (depends on 3)

The method of claim 3, wherein said cancer is selected from non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method of treating pancreatic cancer comprising administering to a patient a compound of a compound of claim 1 in combination with an additional therapeutic agent selected from Gemcitabine, radiation therapy, or both Gemcitabine and radiation therapy together.

### Claim at position 15

24-39. (canceled)

### Claim 40 (depends on 1)

A method of treating non-small cell lung cancer comprising administering to a patient a compound of claim 1 in combination with one or more of the following additional therapeutic agents: Cisplatin or Carboplatin, Etoposide, and ionizing radiation.

### Claim at position 17

41-43. (canceled)

### Claim 44 (depends on 1)

A method of inhibiting ATR in a biological sample comprising the step of contacting a compound of claim 1 with said biological sample.

### Claim 45 (depends on 44)

The method of claim 44, wherein said biological sample is a cell.

### Claim 46 (depends on 1)

A method of sensitizing cells to DNA damaging agents comprising administering to a patient a compound of claim 1.

### Claim 47 (depends on 46)

The method of claim 46 wherein said cell is a cancer cell having defects in the ATM signaling cascade, wherein said defect is altered expression or activity of one or more of the following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or SMC1.

### Claim at position 22

48-49. (canceled)

### Claim 50 (depends on 3)

The method of claim 3, wherein said cell is a cancer cell expressing DNA damaging oncogenes.

### Claim 51 (depends on 50)

The method of claim 50, wherein said cancer cell has altered expression or activity of one or more of the following: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A and Rb.

### Claim 52 (depends on 3)

The method of claim 3, wherein said cancer, cancer cell, or cell has a defect in a base excision repair protein.

### Claim 53 (depends on 52)

The method of claim 52, wherein the base excision repair protein is UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and phosphatase); PARP1, PARP2(Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1 (endonuclease) or Aprataxin.

### Claim at position 27

54-59. (canceled)

### Claim 60 (depends on 3)

The method of claim 3 further comprising administering to said patient an additional therapeutic agent selected from Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also known as BSI-201 or SAR240550), Veliparib (also known as ABT-888), Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or AZD2461.

### Claim at position 29

61-76. (canceled)
